According to Gentian Diagnostics ASA's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 66.5888. At the end of 2023 the company had a P/E ratio of -60.1.
Year | P/E ratio | Change |
---|---|---|
2023 | -60.1 | 124.44% |
2022 | -26.8 | -40.08% |
2021 | -44.7 | -7.28% |
2020 | -48.2 | 100.19% |
2019 | -24.1 | -45.47% |
2018 | -44.2 | 16.81% |
2017 | -37.8 | -42.8% |
2016 | -66.1 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.